Blood · 5 Nov 2026
MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma
Carmen Gonzalezh-index 4, Camila Guerrero, Marta Larrayoz, Aintzane Zabaleta, Junfei Zhao, Ioannis V. Kostopoulos, Ourania E. Tsitsilonis, Evangelos Terpos, Norma C. Gutiérrez, Manuela Fernández, María-José Calasanz, Paula Rodriguez-Otero, Felipe Prosper, Teresa Lozano, Juan-José Lasarte, Benjamin L. Ebert, Albert Oriol, Anna Sureda, Maria-Jesus Blanchard, Yolanda Gonzalez, Joan Bargay, Sunil Lakhwani, Rafael Rios-Tamayo, Laura Rosiñol, Joaquin Martinez-Lopez, Juan-José Lahuerta, Joan Blade, Maria-Victoria Mateos, Jesús F. San Miguel, Maria-Teresa Cedena, Noemi Puig, Patrick Hagner, Maria Ortiz, José Angel Martinez-Climent, Bruno Paivah-index 72
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- Crossref1
- OpenCitations0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract The clinical significance of 1 or 2 measurable residual disease (MRD) assessments is established in multiple myeloma (MM). However, how to stratify patients according to ≥3 MRD assessments remains unknown. The traits of MRD resistance and whether treatment of persistent MRD vs relapse could improve outcomes remains unknown. MRD dynamics were computed using next-generation flow cytometry and CONNECTOR in 539 patients with newly diagnosed MM with ≥3 assessments in the GEM2012MENOS65/GEM2014MAIN and GEM2017FIT trials. Molecular and immune profiling were performed in matched diagnostic and MRD samples. The survival impact of treating persistent MRD vs relapse was investigated with anti–B-cell maturation antigen (anti-BCMA) chimeric antigen receptor (CAR) T cells in MIcγ1hCRBN mice. Computed MRD dynamics based on 3610 MRD assessments identified 5 subgroups with different survival. Patients with late-sustained MRD response had excellent outcomes, similar to those with early sustained MRD response. Patients with volatile results and those with primarily and resurgent MRD resistance had dismal survival. MRD dynamics outperformed transplant eligibility and the Revised International Staging System. These results were validated in 249 patients with MM treated in routine practice. Multiomics characterization of MRD dynamics in patients and mouse models of MRD resistance revealed genomic evolution, transcriptional adaptation, and a proinflammatory tumor-immune microenvironment. Increasing clonality and exhaustion of endogenous T cells throughout disease progression urged investigating whether MRD interception with anti-BCMA CAR T cells could improve outcomes. Infusion at MRD resistance prolonged mouse survival compared with identical treatment at relapse. In summary, MRD dynamics is the strongest predictor of progression and may help tailoring treatment to prevent additional tumor and immune alterations before relapse.
What the data shows
- Crossref counts 1 citations, the most of the databases. The others count 0.
- Bruno Paiva has the highest h-index among the authors (72).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (53)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 33 more references
A free account opens the rest of the citing papers and references on every paper’s page.